QUYRIUX® OROPHAX 360: Mucositis conditioning and treatment gel

Innovative product used as a base for the conditioning and treatment of oncological mucositis and associated complications along the entire digestive tract.

ETHIOPATHOGENY: Mucositis is caused by inhibition of DNA replication caused by chemotherapy, and thus inhibition of mucosal cell proliferation, leading to mucosal atrophy and ulceration.

EPIDEMIOLOGY: It affects approximately 40% of patients receiving chemotherapy at standard doses and 76% or more at high doses. 59% of patients treated with mTOR experience mucositis.


  • Xerostomia (dry mouth).
  • Dysgeusia (altered sense of taste).
  • Dysphagia (difficulty in swallowing).
  • Odynophagia (pain when swallowing).
  • glossodynia (burning in the mouth).
  • Gastric disorders (nausea and vomiting, loss of appetite).
  • oesophagitis (inflammation of the lining of the oesophagus).
  • cachexia (weight loss).
  • Local opportunistic infections.


Conditioning: Providing elements that reinforce the mucosa and prepare it, putting it in a better position to receive CT and/or RT treatment.

Protecting: The presentation in gel form creates a protective layer over the entire oral, esophageal and gastric mucosa, in addition some of the elements of the formula exert a protective effect against the damage produced by CT and RT.

Regenerating: Providing elements that accelerate the regeneration of the damaged mucosa, normalizing it, and reducing recovery time.

Anti-infective: Including in its formula natural agents that reduce and treat opportunistic infections (bacteria, fungus, virus…)


  1. Symptom relief: Reduces the symptoms of the adverse effects of CT and RT, improving the quality of life and the patient’s prognosis.
  2. Uninterrupted treatment: It favors compliance with treatment cycles, often interrupted or delayed due to the persistence of side effects.
  3. Patient prognosis: Because it minimizes the impact treatments have on the patient’s quality of life, eliminating or minimizing the adverse effects of the oro/pharyngeal/digestive mucosa, which prevent a normalized feeding of the patient, and a delay of the treatment plan.